Cost-effectiveness of introducing the conjugated pneumococcal vaccine to routine free immunizations for infants in Lazio, Italy

摘要: Abstract Objective To examine the health outcomes and costs of a hypothetical pneumococcal vaccination campaign among general infant population in Lazio region (Italy). Methods We developed model simulating direct medical vaccinating infants with conjugated vaccine (PCV-7) compared to (in outpatient) treating disease, from public service perspective. According trials’ outcomes, we considered effectiveness preventing part invasive disease (IPD), pneumonia any aetiology, acute otitis moedia. Age-specific incidence, mortality care came local surveillance surveys; €40/dose. Annual budgetary impact macro-health benefits were predicted for 2005–2014. Cost-effectiveness was expressed as net healthcare per disability-adjusted life-year (DALY) gained. Results After 10 years, five cases meningitis, 20 IPD, 933 pneumonia, 406 pneumonia-related hospitalisations, 3160 would be averted annually by vaccinating. The annual cost €4.9 m, €1.4 m. Additional mass decrease over time €5.1 m €3.5 m year. At baseline, DALY €18.0 k, if are not discounted, €51.7 k adopting 3.5% discount rate; it 12% lower hypothesis high IPD incidence 68% 50% less. Conclusions makes more expensive than today's recommended vaccinations. Nevertheless, cost-effectiveness introducing PCV-7 compares favourably previous estimates similar countries.